Literature DB >> 2397573

Evidence against the "early protection-delayed death" hypothesis of superoxide dismutase therapy in experimental myocardial infarction. Polyethylene glycol-superoxide dismutase plus catalase does not limit myocardial infarct size in dogs.

M Tanaka1, R C Stoler, G P FitzHarris, R B Jennings, K A Reimer.   

Abstract

We previously found that superoxide dismutase (SOD) did not limit myocardial infarct size after 40 or 90 minutes of ischemia and 4 days of reperfusion in dogs. Because some other studies have shown limitation of infarct size after shorter periods of reperfusion, we postulated that our negative results might be due to late reperfusion injury mediated by superoxide anions produced after excretion of SOD. To test this "early protection-delayed death" hypothesis, we have examined whether SOD, conjugated to polyethylene glycol (PEG-SOD) to prolong its circulating half-life, limited myocardial infarct size. The circumflex artery was occluded for 90 minutes followed by 4 days of reperfusion. PEG-SOD (total dose, 10,000 units/kg) and catalase (55,000 units/kg) were given during the 30 minutes before reperfusion. Plasma SOD levels in the treated group were 330 +/- 20 units/ml at the onset of reperfusion and 140 +/- 10 units/ml on day 4 (circulating half-life, 75 +/- 5 hours) versus 5 +/- 1 units/ml in controls. Histological infarct size was 37.1 +/- 4.2% of the area at risk in the treated group (n = 11) versus 44.5 +/- 6.2% in controls (n = 10) (p = NS). Infarct size and collateral blood flow were inversely related in controls; PEG-SOD and catalase did not shift this regression (p = NS by analysis of covariance). Thus, infarct size was not limited when measured after 4 days of reperfusion, even though plasma SOD exceeded 100 units/ml throughout this reperfusion period.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2397573     DOI: 10.1161/01.res.67.3.636

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  5 in total

1.  Lethal Reperfusion Injury: Does It Exist and Does It Matter?

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997-01       Impact factor: 2.300

2.  Protective effect of edaravone against hypoxia-reoxygenation injury in rabbit cardiomyocytes.

Authors:  Masahiro Yamawaki; Norihito Sasaki; Masaki Shimoyama; Junichiro Miake; Kazuhide Ogino; Osamu Igawa; Fumito Tajima; Chiaki Shigemasa; Ichiro Hisatome
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

Review 3.  Is Cardioprotection Dead?

Authors:  David J Lefer; Eduardo Marbán
Journal:  Circulation       Date:  2017-07-04       Impact factor: 29.690

4.  Effect of edaravone, a novel free radical scavenger, supplemented to cardioplegia on myocardial function after cardioplegic arrest: in vitro study of isolated rat heart.

Authors:  Kazuhiro Yamazaki; Senri Miwa; Shinya Toyokuni; Shintaro Nemoto; Wnimunk Oriyanhan; Kiyoaki Takaba; Yoshiaki Saji; Akira Marui; Takeshi Nishina; Tadashi Ikeda; Masashi Komeda
Journal:  Heart Vessels       Date:  2009-05-24       Impact factor: 2.037

5.  Superoxide Dismutase-Loaded Nanoparticles Attenuate Myocardial Ischemia-Reperfusion Injury and Protect Against Chronic Adverse Ventricular Remodeling.

Authors:  Peter J Altshuler; Alexis R Schiazza; Lijun Luo; Mark R Helmers; Bonirath Chhay; Jason J Han; Robin Hu; D Alan Herbst; Andrew Tsourkas; Zhiliang Cheng; Pavan Atluri
Journal:  Adv Ther (Weinh)       Date:  2021-04-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.